DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mrx33k/global_and) has announced the addition of the "Global and Chinese Stem Cell Industry Report, 2015-2018" report to their offering.
Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hundreds of diseases in clinical studies, of which about 50% is applied to blood diseases. In addition to blood diseases, tumors, neurological system diseases, heart disease, immune system diseases and the like are also important fields of stem cell clinical research.
Up to now, only 12 sorts of stem cell products have been approved for marketing after rigorous safety and effectiveness review worldwide. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. allowance funds) and the capital support of key partners, very few companies have dropped out.
Considerable stem cell therapy products are in clinical trials worldwide. For example, the United States National Institutes of Health (NIH) had registered 4,293 cord blood-related clinical research projects as of December 23, 2014 and 5,190 ones as of November 17, 2015, including 484 ones in East Asia.
Restricted by policies, capital, technology and other factors, China's stem cell therapy develops slowly. At present, China has not approved any stem cell drug product for marketing. As for stem cell research, Chinese authorities have not accepted or reviewed any stem cell therapy of any medical institution except hematopoietic stem cells suitable for treating blood diseases; besides, the stem cell clinical applications of some hospitals pertain to the scope of pilot clinical studies.
Global and China Stem Cell Industry Report, 2015-2018 highlights the followings:
- Classification, application, industry chain definition, etc. of stem cells;
- Major enterprises, policies, upstream/midstream/downstream development and prospects, etc. of global stem cell industry;
- Policies, upstream/midstream/downstream development, etc. of China stem cell industry;
- Operation, stem cell business, etc. of 8 upstream companies and 20 midstream/downstream companies worldwide.
Key Topics Covered:
1. Overview of Stem Cell Industry
2. Global Stem Cell Industry Chain
3. China Stem Cell Industry Chain
4. Upstream Enterprises
5. Midstream and Downstream Enterprises
- Athersys
- Beike Biotechnology
- Caladrius Biosciences
- Celgene
- Cellular Biomedicine
- Cryo-Cell International
- Cryosite
- Cyagen Biosciences
- Cytori Therapeutics
- Esperite
- Golden Meditech
- Health & Biotech
- LifeCell International
- MEDIPOST
- Mesoblast
- Ocata
- Opexa Therapeutics
- Orthofix International
- Osiris Therapeutics
- Pluristem Therapeutics
- Reneuron
- SALIAI
- StemCells
- Tian Qing Stem Cell
- Tigenix
- VCANBIO
- Vitro Biopharma
- ZhongKe Biopharm
For more information visit http://www.researchandmarkets.com/research/mrx33k/global_and
